GlassScriptPhysician profile
Shayma Kazmi
NPI 1801919550
$619,075.76
in general payments reported to CMS, 2019-2025
32 companies · $30K in 2025
The $30K reported for 2025 was more than what 92% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231K · 2020: $118K · 2021: $114K · 2022: $43K · 2023: $51K · 2024: $32K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $8,898 · Travel and Lodging: $6,520 · Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,453.50 |
| Consulting Fee | $8,897.50 |
| Travel and Lodging | $6,520.33 |
| Food and Beverage | $2,283.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $147,516.89 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115,751.48 | 2019-2024 | Alunbrig |
| Jazz Pharmaceuticals INC. | $115,678.40 | 2019-2025 | Zepzelca |
| Foundation Medicine, INC. | $81,790.68 | 2019-2023 | Foundationone Cdx |
| Merck Sharp & Dohme LLC | $54,853.17 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Eisai INC. | $43,689.82 | 2019-2021 | |
| Amgen INC. | $20,276.66 | 2024-2025 | Imdelltra (Amg757) |
| Astrazeneca Pharmaceuticals LP | $11,235.44 | 2019-2025 | Tagrisso |
| Gilead Sciences, INC. | $8,046.50 | 2021 | |
| Eli Lilly and Company | $5,259.95 | 2021-2022 | |
| Pfizer INC. | $3,440.64 | 2019-2023 | |
| Immunomedics, INC. | $2,812.50 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,673.40 | 2019-2023 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $1,725.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,591.64 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,397.88 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Emd Serono, INC. | $520.25 | 2019-2021 | |
| Novocure INC. | $366.98 | 2019-2024 | Optune |
| Daiichi Sankyo INC. | $131.67 | 2024-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $107.80 | 2019-2021 | |
| Tesaro, INC. | $48.21 | 2019 | |
| Alcresta Therapeutics, INC. | $41.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.52 | 2020 | |
| Pharmacosmos Therapeutics INC. | $20.37 | 2025 | Monoferric |
| Incyte Corporation | $19.39 | 2019 | |
| Clovis Oncology, INC. | $15.00 | 2019 | |
| Celgene Corporation | $14.91 | 2024 | Pomalyst |
| Shire North American Group INC | $14.87 | 2019 | |
| Genentech USA, INC. | $13.80 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayma Kazmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.